GlaxoSmithKline UK

Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com

Patient Information Leaflet last updated on the eMC: 10/05/2011
PIL Relenza 5mg/dose inhalation powder

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 10/05/2011 and displayed until Current
Reasons for adding or updating:
  • Change/addition of instructions for reconstitution and/ or administration
  • Change to date of revision
  • Change to side-effects
Updated on 29/07/2010 and displayed until 10/05/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 26/10/2009 and displayed until 29/07/2010
Reasons for adding or updating:
  • Change to date of revision
Updated on 30/04/2008 and displayed until 26/10/2009
Reasons for adding or updating:
  • Transfer to upgraded management system
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 25/01/2008 and displayed until 30/04/2008
Reasons for adding or updating:
  • Change due to user-testing of patient information
Updated on 04/11/2005 and displayed until 25/01/2008
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 31/10/2005 and displayed until 04/11/2005
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 16/01/2004 and displayed until 31/10/2005
Reasons for adding or updating:
  • Update to PIL
Updated on 24/09/2001 and displayed until 16/01/2004
Reasons for adding or updating:
  • Update to PIL
Updated on 15/11/2000 and displayed until 24/09/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   zanamivir